ECSP22060286A - Célula cho que expresa heterodímeros il–15 - Google Patents

Célula cho que expresa heterodímeros il–15

Info

Publication number
ECSP22060286A
ECSP22060286A ECSENADI202260286A ECDI202260286A ECSP22060286A EC SP22060286 A ECSP22060286 A EC SP22060286A EC SENADI202260286 A ECSENADI202260286 A EC SENADI202260286A EC DI202260286 A ECDI202260286 A EC DI202260286A EC SP22060286 A ECSP22060286 A EC SP22060286A
Authority
EC
Ecuador
Prior art keywords
cho cell
heterodimers
cell expressing
heterodimer
il15ralpha
Prior art date
Application number
ECSENADI202260286A
Other languages
English (en)
Inventor
Justyna Jozefczuk
Alexandre Aurélien Pons
Thomas Jostock
Urs Ulrich Lohrig
Richard Gabriel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22060286A publication Critical patent/ECSP22060286A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al heterodímero de IL–15/IL–15Ralfa producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero.
ECSENADI202260286A 2020-02-05 2022-08-01 Célula cho que expresa heterodímeros il–15 ECSP22060286A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05

Publications (1)

Publication Number Publication Date
ECSP22060286A true ECSP22060286A (es) 2022-09-30

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202260286A ECSP22060286A (es) 2020-02-05 2022-08-01 Célula cho que expresa heterodímeros il–15

Country Status (22)

Country Link
US (1) US20210244821A1 (es)
EP (1) EP4100425A1 (es)
JP (2) JP2022522566A (es)
KR (1) KR20220137651A (es)
CN (1) CN115023436A (es)
AR (1) AR121261A1 (es)
AU (1) AU2021215893A1 (es)
BR (1) BR112022014493A2 (es)
CA (1) CA3168469A1 (es)
CL (2) CL2022002094A1 (es)
CO (1) CO2022010860A2 (es)
CR (1) CR20220367A (es)
DO (1) DOP2022000156A (es)
EC (1) ECSP22060286A (es)
IL (1) IL295278A (es)
JO (1) JOP20220174A1 (es)
MX (1) MX2022009611A (es)
PE (1) PE20221509A1 (es)
PH (1) PH12022552029A1 (es)
TW (1) TWI893058B (es)
UY (1) UY39062A (es)
WO (1) WO2021156720A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
TW202434276A (zh) 2022-11-04 2024-09-01 瑞士商諾華公司 Ｎｋｇ２ｄ融合蛋白癌症療法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
MX357691B (es) * 2006-01-13 2018-07-19 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
EP2326531B2 (en) 2008-08-22 2021-01-13 Magna Seating Inc. Disc recliner with reduced backlash
WO2010072676A1 (en) * 2008-12-22 2010-07-01 Lek Pharmaceuticals D.D. Mammalian expression vector
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP3851459B1 (en) * 2010-09-21 2024-05-01 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
WO2012094627A2 (en) * 2011-01-06 2012-07-12 The Johns Hopkins University Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells
EP2911684B1 (en) * 2012-10-24 2019-06-19 Novartis Ag Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
MX368664B (es) * 2014-04-29 2019-10-10 Novartis Ag Células novedosas de vertebrados y métodos para la expresión recombinante de un polipéptido de interés.
EP3015475A1 (en) * 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
SI3235830T1 (sl) * 2014-12-19 2020-12-31 Jiangsu Hengrui Medicine Co., Ltd. Proteinski kompleks interlevkina 15 in njegove uporabe
EP3390643B8 (en) * 2015-12-18 2023-08-02 OncoSec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
JP7200104B2 (ja) * 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
PE20240950A1 (es) * 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EP3529263B1 (en) * 2016-10-21 2025-08-06 Altor BioScience Corporation Multimeric il-15-based molecules
JP2020505350A (ja) * 2017-01-20 2020-02-20 ノバルティス アーゲー 癌の治療のための組合せ療法
JP2021512104A (ja) * 2018-02-02 2021-05-13 ノバルティス アーゲー 癌の治療のためのＳＴＩＮＧアゴニスト及びＩＬ−１５／ＩＬ１５−Ｒａの組合せ
BR112020015202A2 (pt) * 2018-03-01 2020-12-29 Glycotope Gmbh Construções de proteínas de fusão compreendendo um anticorpo anti-muc1 e il-15

Also Published As

Publication number Publication date
CN115023436A (zh) 2022-09-06
CL2023002447A1 (es) 2024-03-15
JP2023145622A (ja) 2023-10-11
PE20221509A1 (es) 2022-10-04
CL2022002094A1 (es) 2023-03-10
TWI893058B (zh) 2025-08-11
US20210244821A1 (en) 2021-08-12
CA3168469A1 (en) 2021-08-12
AR121261A1 (es) 2022-05-04
CO2022010860A2 (es) 2022-08-19
TW202142558A (zh) 2021-11-16
JOP20220174A1 (ar) 2023-01-30
EP4100425A1 (en) 2022-12-14
CR20220367A (es) 2022-08-30
DOP2022000156A (es) 2022-10-16
UY39062A (es) 2021-09-30
BR112022014493A2 (pt) 2022-09-20
PH12022552029A1 (en) 2023-11-20
MX2022009611A (es) 2022-11-07
JP2022522566A (ja) 2022-04-20
WO2021156720A1 (en) 2021-08-12
KR20220137651A (ko) 2022-10-12
AU2021215893A1 (en) 2022-08-25
IL295278A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
ECSP22060286A (es) Célula cho que expresa heterodímeros il–15
CL2018000101A1 (es) Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469)
CL2020000966A1 (es) Tratamiento de enfermedad mediada por smc
MX2017010673A (es) Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MX380709B (es) Metodo de inoculacion de plantas.
MX378280B (es) Metodo para producir refuerzo de pilar central.
MX381257B (es) Composición polimérica reforzada con fibra.
MX2019010709A (es) Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
MX385366B (es) Inoculantes y metodos para su uso.
MX2021003654A (es) Metodo para seleccionar neoepitopes.
BR112017023560A2 (pt) composição de polímero reforçada com fibra, e, artigo.
RU2017124228A (ru) Эластичный ламинат, содержащее его изделие, растянутый эластичный ламинат и содержащее его изделие
UY38243A (es) Anticuerpos anti-tmeff2 monoespecíficos y multiespecíficos y sus usos
MX2018013565A (es) Métodos para tratar la leucemia mieloide aguda y mieloma múltiple usando células asesinas naturales.
MX2021013254A (es) Metodo para producir una pelicula compuesta de capas multiples, pelicula compuesta de capas multiples y uso de la misma.
MX2023012851A (es) Métodos de tratamiento y seguimiento de la enfermedad de parkinson.
AR091181A1 (es) Proceso para la produccion de metil metacrilato y polimeros o copolimeros del mismo
MX2025004503A (es) Productos de anticuerpos contra el receptor tipo inmunoglobulina leucocitaria b2 (lilrb2) y metodos
AR116481A1 (es) Biomaterial que comprende células madre derivadas de tejido adiposo y gelatina y método para producir el mismo
MX2017005896A (es) Metodo para producir un escariador.
UY40028A (es) Unidades de unión multiespecíficas que comprenden los dominios de unión a pd-1 y tgf-brii
CO2024015993A2 (es) Anticuerpos anti-tnfr2 y métodos de uso de estos
Giunashvili Studia Litteraria Universitatis Iagellonicae Cracoviensis, Volume 14 (2019), Special Issue. A Volume in Honour of Professor Anna Krasnowolska. Editor-in-Chief: Celina Juda
García Vázquez Redefining the precariat from the Chinese perspective
BR112022025861A2 (pt) Gel vaginal